In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...

(KPLC) - Nearly 40 million Americans struggle with sleep apnea, but a drug approved in December may help. The U.S. Food and Drug Administration calls Zepbound the first and only prescription medicine ...

ResMed stock is down today, even though the maker of CPAPs and other respiratory treatment devices had Street-beating Q2 ...

ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst was upbeat.

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...